Evidence map›Paper›PMID 38057857›Full record

ArticleJournal of translational medicine2023

Endothelial progenitor cells systemic administration alleviates multi-organ senescence by down-regulating USP7/p300 pathway in chronic obstructive pulmonary disease.

Wenhua Wang, Huaihuai Peng, Menghao Zeng, Jie Liu, Guibin Liang, Zhihui He

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Endothelial progenitor cells and chronic obstructive pulmonary disease: From basic research to clinical application.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenhua Wang *Department of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huaihuai Peng *Department of Intensive Care Unit, Hunan Province Directly Affiliated Traditional Chinese Medicine Hospital, Zhuzhou, Hunan, China.
Menghao ZengDepartment of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jie LiuDepartment of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Guibin LiangDepartment of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhihui HeDepartment of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. hzh703@csu.edu.cn.ORCID 0000-0001-5672-9691
Central South University · CNHunan Academy of Traditional Chinese Medicine · CN

Funding

the National Natural Science Foundation of China 81870040
6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) has impacted approximately 390 million people worldwide and the morbidity is increasing every year. However, due to the poor treatment efficacy of COPD, exploring novel treatment has become the hotpot of study on COPD. Endothelial progenitor cells (EPCs) aging is a possible molecular way for COPD development. We aimed to explore the effector whether intravenous administration of EPCs has therapeutic effects in COPD mice.

methodsCOPD mice model was induced by cigarette smoke exposure and EPCs were injected intravenously to investigate their effects on COPD mice. At day 127, heart, liver, spleen, lung and kidney tissues of mice were harvested. The histological effects of EPCs intervention on multiple organs of COPD mice were detected by morphology assay. Quantitative real-time PCR and Western blotting were used to detect the effect of EPCs intervention on the expression of multi-organ senescence-related indicators. And we explored the effect of EPCs systematically intervening on senescence-related USP7/p300 pathway.

resultsCompared with COPD group, senescence-associated β-galactosidase activity was decreased, protein and mRNA expression of p16 was down-regulated, while protein and mRNA expression of cyclin D1 and TERT were up-regulated of multiple organs, including lung, heart, liver, spleen and kidney in COPD mice after EPCs system intervention. But the morphological alterations of the tissues described above in COPD mice failed to be reversed. Mechanistically, EPCs systemic administration inhibited the expression of mRNA and protein of USP7 and p300 in multiple organs of COPD mice, exerting therapeutic effects.

conclusionsEPCs administration significantly inhibited the senescence of multiple organs in COPD mice via down-regulating USP7/p300 pathway, which presents a possibility of EPCs therapy for COPD.

Indexed as

Endothelial Progenitor CellsPulmonary Disease, Chronic ObstructiveSignal TransductionAnimalsCellular SenescenceDown-RegulationHumansMiceRNA, MessengerUbiquitin-Specific Peptidase 7RNA, MessengerUbiquitin-Specific Peptidase 7COPDEPCsp300SenescenceSystemic administrationUSP7

Identifiers

PMID38057857
PMCPMC10699081
OpenAlexW4389398242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.